Red blood cell wide variety of endogenous mediators and xenobiotics. Excessive eryptosis is observed in red blood cells lacking the cGMP-dependent protein kinase type I or the AMP-activated protein kinase AMPK. Inhibitors of eryptosis include erythropoietin, nitric oxide, catecholamines and high concentrations of urea. Much of the resulting breakdown products are recirculated in the body. The heme constituent of hemoglobin are broken down into iron (Fe) and biliverdin. The biliverdin is reduced to bilirubin, which is released into the plasma and recirculated to the liver bound to albumin. The iron is released into the plasma to be recirculated by a carrier protein called
Genetically engineered blood protein and a substance of choice, such as a small-molecule therapeutic agent or an antibody. The modifications leave the cells and their surfaces otherwise intact. One application is to engineer red blood cells into drug-delivery vehicles. Mature red cells carry no genetic material, potentially presenting fewer safety risks than other gene and cell therapies. Human red blood cells circulate for as long as four months, meaning they could potentially form the basis of long-term therapies. The cells move throughout body via the bloodstream and are unnoticed by the immune system. Genetically engineered blood Genetically engineered blood is blood that has